North America Inhaled Nitric Oxide Market By Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications), By Country, Industry Analysis and Forecast, 2020 -

The North America Inhaled Nitric Oxide Market is expected to witness market growth of 6.1% CAGR during the forecast period (2020-2026).

This nitric oxide can be inhaled via the nose or mouth, which helps in relaxing the smooth muscles to broaden all the blood vessels in the oxygenated regions of the lungs. It is mostly utilized together with the ventilator and other components to cure pulmonary hypertension in newborn babies and adults with respiratory problems.

It is clinically proven that nitric oxide gas is effective in enlarging blood vessels to ease down the muscle tension that takes in oxygen more efficiently in the body. Moreover, nitric oxide is mostly utilized in breathing systems like ventilators. The inhaled nitric oxide is regarded as a strong & selective pulmonary vasodilator, which does not reduce systemic vascular tone.

It is considered that INO therapy was effective to enhance oxygenation in newborn babies with persistent pulmonary hypertension of the newborn (PPHN). It is due to its selective pulmonary vasodilator effects, inhaled nitric oxide therapy is a crucial treatment for term newborns with hypoxemic respiratory problems because of PPHN. In 1999, the Food and Drug Administration of the U.S. had first approved Inhaled Nitric Oxide for its usage as a medical gas to cure hypoxic respiratory failure related to the clinical or echocardiographic confirmation of pulmonary hypertension in term and late preterm infants. Afterward, inhaled nitric oxide therapy is clinically used to cure PPHN in term and late preterm infants without consensus.

Based on Application, the market is segmented into Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The Neonatal Respiratory Treatment market dominated the Canada Inhaled Nitric Oxide Market by Application in 2019, growing at a CAGR of 6 % during the forecast period. The Chronic Obstructive Pulmonary Disease (COPD) market is expected to witness a CAGR of 7.1% during (2020 - 2026).

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Getinge AB, Merck Group, Halma PLC, Linde PLC (Praxair, Inc.), Air Liquide S.A., Beyond Air, Inc., Mallinckrodt PLC (International Minerals and Chemical Corporation), VERO Biotech LLC, Nu-Med Plus, Inc. and Novoteris, LLC.

Scope of the Study

Market Segments covered in the Report:

By Application

• Neonatal Respiratory Treatment
• Chronic Obstructive Pulmonary Disease (COPD)
• Acute Respiratory Distress Syndrome (ARDS)
• Other Applications

By Country

• US
• Canada
• Mexico
• Rest of North America

Companies Profiled

• Getinge AB
• Merck Group
• Halma PLC
• Linde PLC (Praxair, Inc.)
• Air Liquide S.A.
• Beyond Air, Inc.
• Mallinckrodt PLC (International Minerals and Chemical Corporation)
• VERO Biotech LLC
• Nu-Med Plus, Inc.
• Novoteris, LLC

Unique Offerings from the Publisher

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free